Phapros Swings to Rp27.44 Billion Profit in 2025
Phapros, a pharmaceutical state-owned enterprise subsidiary of PT Kimia Farma Tbk, booked a consolidated profit for the year of Rp27.44 billion in 2025, driven by increased sales and production cost efficiencies amid global pharmaceutical industry pressures.
“In terms of consolidated profit for the year, a figure of Rp27.44 billion was achieved in 2025, a positive reversal compared to 2024 which still recorded a loss of Rp290.63 billion,” said Phapros Director of Finance, Risk Management and Human Resources Ferdinand Troedu during the company’s Public Expose following the Annual General Meeting of Shareholders for the 2025 fiscal year in Jakarta on Thursday.
Ferdinand stated consolidated net sales throughout 2025 reached Rp940.9 billion, an increase of 26.3% compared to the previous year’s realisation of Rp744.7 billion. He said the achievement was driven by fundamental business strategies executed by the company throughout 2024-2025, including supply chain improvements, commercialisation strengthening, and customer segment diversification.
Furthermore, the company’s gross profit also increased to Rp492.5 billion in 2025 from Rp270.66 billion in 2024. “This also reflects the success of production and procurement efficiency initiatives,” he noted. The ratio of cost of goods sold to sales dropped by 16 percentage points year-on-year, supporting the improvement in the company’s profitability.
Director of Production Ida Rahmi Kurniasih said the company increased production utilisation to 72.65% in 2025. Additionally, the company recorded procurement cost savings of Rp28.4 billion through joint procurement of raw materials.
In terms of distribution and marketing, the company also recorded growth in several segments. “The Pharmaceutical Wholesaler segment grew by 9.7%. Furthermore, non-affiliated distributor transaction outlets increased by 89.6%,” said Ida.
In the first quarter of 2026, the company continued its growth trend by recording consolidated net sales of Rp221.1 billion, up 10.2% compared to the same period the previous year of Rp200.7 billion. The company’s earnings before interest, taxes, depreciation, and amortisation were recorded at Rp24.6 billion, an increase of 64% compared to the first quarter of 2025 of Rp15 billion. Meanwhile, comprehensive profit for the current period turned positive to Rp761.5 million compared to the first quarter of 2025 which still recorded a loss of Rp5.9 billion.
President Director Intan Abdams Katoppo said the company will continue its fundamental business strengthening strategy in 2026 through cost efficiency, working capital strengthening, product portfolio development, and export market expansion. She mentioned the company will expand export markets to Timor-Leste, Cambodia, the Philippines, Myanmar, Papua New Guinea, and Peru.
During the AGM for the 2025 fiscal year, the company also agreed on a cash dividend distribution of 15% of net profit, or valued at Rp4.12 billion. “After two consecutive years of not providing dividends, shareholders can finally receive dividends again,” Intan revealed.
Source: jawawa.id (https://jawawa.id/newsitem/phapros-swings-to-rp27-44-billion-profit-in-2025-1781186545)
Originally published by Antara (Indonesian) (https://www.antaranews.com/berita/5604500/phapros-bukukan-laba-rp2744-miliar-pada-2025), translated from Indonesian